These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Sisó A, Ramos-Casals M, Bové A, Brito-Zerón P, Soria N, Muñoz S, Testi A, Plaza J, Sentís J, Coca A. Lupus; 2008 Apr; 17(4):281-8. PubMed ID: 18413408 [Abstract] [Full Text] [Related]
6. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942 [Abstract] [Full Text] [Related]
7. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751 [Abstract] [Full Text] [Related]
8. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Arthritis Rheum; 2009 Jan 15; 61(1):29-36. PubMed ID: 19116963 [Abstract] [Full Text] [Related]
9. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus. Chang ER, Pineau CA, Bernatsky S, Neville C, Clarke AE, Fortin PR. J Rheumatol; 2006 Sep 15; 33(9):1780-4. PubMed ID: 16832849 [Abstract] [Full Text] [Related]